New vaccine trial aims to shield frontline workers from deadly mpox

NCT ID NCT02977715

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the JYNNEOS smallpox vaccine in 1,600 healthcare workers in the Democratic Republic of the Congo who are at high risk of catching mpox. The goal was to see if the vaccine can prevent mpox infection and is safe to use. Participants received the vaccine and were monitored for infections, side effects, and immune responses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONKEYPOX VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vaccinia monkeypox prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tshuapa site

    Boende, Tshuapa, Democratic Republic of the Congo